Market Overview

Synthetic Biologics, Intrexon Initiate Development of Novel Biologics for a Subset of Patients Suffering from IBS

Related SYN
Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)
Synthetic Biologics' Novel IBS-C Program Featured in American College of Gastroenterology Poster

Synthetic Biologics (NYSE: SYN) and Intrexon Corporation (NYSE: XON) ("Intrexon"), a leader in synthetic biology, announced today that they have initiated development of novel biologic approaches for the prevention, as well as the acute and chronic treatment of a subset of irritable bowel syndrome (IBS) pathologies specifically caused by auto-antibodies.

Synthetic Biologics intends to utilize intellectual property optioned from Cedars-Sinai Medical Center ("Cedars-Sinai"). According to an increasing body of recent work conducted by Cedars-Sinai, a subset of IBS cases appear to be causally initiated by one or more encounters with acute infectious gastroenteritis, such as the foodborne illness, Campylobacter jejuni. Cedars-Sinai has identified a novel autoimmune target for this subset of IBS cases because of the development of cross-reacting antibodies between a bacterial toxin and a protein important for controlling gastrointestinal motility.

"We are thrilled to begin work with Intrexon for the development of novel biologic therapeutics targeted at preventing and treating auto-antibody-induced IBS. By accessing Intrexon's proprietary technologies and capabilities, we will

See full press release

Posted-In: News Guidance Buybacks Management Global


Related Articles (SYN + XON)

View Comments and Join the Discussion!

Get Benzinga's Newsletters